Stay updated with breaking news from Leukemia Section. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dr Sekeres discusses the FDA approval of quizartinib plus chemotherapy in patients with newly diagnosed, FLT3-ITD–positive AML, key efficacy and safety data from the QuANTUM-First trial, and how this quizartinib regimen addresses an unmet need for older patients in this population.
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business ...
The American Board of Internal Medicine (ABIM) announced new appointments to its Specialty Boards and Approval Committees today.
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an expert review article in Blood Advances examining the development path and...
Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible StatusSEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage